mRNA Melanoma Vaccine Shows Positive Results in Clinical TrialPhase 3 trial of intismeran, a personalized mRNA melanoma vaccine, shows a 42% lower recurrence risk when paired with pembrolizumab. benchmarks ai-bio ai-science ai-finance Marcus Adeyemi 25/10/2026, 13:01 2 minutes to read
